Drugs / Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01789827 | Mar 2014 → Jun 2018 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01789827 ↗ |
| Modality | Diagnostic / imaging agent | “technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy” NCT01789827 ↗ |